Skip to main content
SpringerLink
Log in

Hormones increase breast cancer risk in Dutch transgender women

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. people born with male genitalia who identify with the female gender

  2. people born with female genitalia who identify with the male gender

  3. Most transgender women received a combination of antiandrogens (usually cyproterone acetate, spironolactone) and estrogens (either ethinylestradiol, conjugated estrogens, estradiol patches, estradiol implants, estradiol injections, estradiol valerate, or estradiol gel). Transgender men were treated with either testosterone gel, intramuscular testosterone esters, or oral or intramuscular testosterone undecanoate.

Reference

  • de Blok CJM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 365: [6 pages], 14 May 2019. Available from: URL: https://doi.org/10.1136/bmj.l1652

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hormones increase breast cancer risk in Dutch transgender women. Reactions Weekly 1754, 9 (2019). https://doi.org/10.1007/s40278-019-62242-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-62242-2

Search

Navigation